Products
Platform
Research
Market
Learn
IPO
Compare Mutual Funds
Fund Comparison
Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Fund Details
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹500 | - |
Expense Ratio | 2.28 | - |
NAV | ₹9.56 | - |
Fund Started | 09 Jun 2025 | - |
Fund Size | ₹621.16 Cr | - |
Exit Load | Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year. | - |
Risk
Very High
-
Rating
-
-
Min SIP Amount
₹500
-
Expense Ratio
2.28
-
NAV
₹9.56
-
Fund Started
09 Jun 2025
-
Fund Size
₹621.16 Cr
-
Exit Load
Exit Load for units in excess of 10% of the investment,1% will be charged for redemption within 1 year.
-
Returns
1 Year | - | - |
3 Year | - | - |
5 Year | - | - |
1 Year
-
-
3 Year
-
-
5 Year
-
-
Holding Analysis
Equity | 95.53% | - |
Cash | -0.26% | - |
Equity
95.53%
-
Cash
-0.26%
-
Top Holdings
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
|---|---|
Sun Pharmaceutical Industries Ltd. | 9.25% |
Mankind Pharma Ltd. | 7.29% |
Divi's Laboratories Ltd. | 7.05% |
Apollo Hospitals Enterprise Ltd. | 6.18% |
Max Healthcare Institute Ltd. | 5.54% |
Cipla Ltd. | 5.38% |
Aster DM Healthcare Ltd. | 4.91% |
Abbott India Ltd. | 4.57% |
Astrazeneca Pharma India Ltd. | 4.00% |
Gland Pharma Ltd. | 3.73% |
-
Fund Manager
Name | Sanjay Chawla | - |
Start Date | 09 Jun 2025 | - |
Name
Sanjay Chawla
-
Start Date
09 Jun 2025
-
About Fund
Description | The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. | - |
Launch Date | 09 Jun 2025 | - |
Description
The scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns.
-
Launch Date
09 Jun 2025
-